Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

AAR

- PMLiVE

Amgen, Servier start second phase 3 trial of heart failure hope

Treatment is one of few in underserved area

- PMLiVE

Greater Manchester backs move to outcome-based payment

Region teams up with Cancer Research UK to accelerate change

- PMLiVE

As government rushes through no-deal legislation, UK biotech repeats Brexit plea

UK market would be relegated in importance

- PMLiVE

‘Inflexible’ NICE blocking access to rare disease drugs

Spinraza most high profile example of access problem

- PMLiVE

Big opportunities in big data, but EMA and industry just getting started

250m genomes sequenced, but data trapped in silos

- PMLiVE

Biosimilar Herceptin helps Roche gain new Perjeta recommendation

NICE decision puts NHS in vanguard for new use

- PMLiVE

No deal Brexit would see UK miss out on ‘safest medicines system in the world’

Health leaders say it would be 'a travesty'

- PMLiVE

Skills shortage and Brexit will hit R&D, warns UK pharma

Skill shortages and Brexit seen as greatest threat

- PMLiVE

Medicines will take priority over food in no-deal Brexit

The UK is more reliant on the EU for medicines than food, says Hancock

- PMLiVE

European Medicines Agency departs London ahead of Brexit

Regulator moving to Amsterdam, as Novartis adds voice to no-deal warnings

- PMLiVE

Ministerial revolt looming over ‘no-deal’ Brexit risk

Airbus CEO says no-deal Brexit could force it to relocate

- PMLiVE

EMA says Lilly’s Lartruvo should not be prescribed

First time EMA has acted on accelerated approval follow-up

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links